MedTrace Logo

Goal Oriented Strategy to Preserve Ejection Fraction Trial

NCT03236818 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2017-08-02

No results posted yet for this study

Summary

In this prospective long term feasibility study we examine whether a goal oriented therapeutic strategy that is able to preserve right ventricular function will result in improved clinical outcome in patients with pulmonary arterial hypertension. We hypothesize that right ventricular function can only be preserved when early and aggressive medical combination therapy not only reduces pulmonary vascular resistance but also pulmonary pressures.

Conditions

Interventions

DRUG

ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)

Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)

Sponsors & Collaborators

  • Amsterdam UMC, location VUmc

    lead OTHER

Principal Investigators

  • Anton Vonk Noordegraaf, MD, PhD · VU University Medical Center, department of pulmonary diseases

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03236818 on ClinicalTrials.gov